200 related articles for article (PubMed ID: 30064384)
1. Cytoplasmic TRAIL-R1 is a positive prognostic marker in PDAC.
Gundlach JP; Hauser C; Schlegel FM; Böger C; Röder C; Röcken C; Becker T; Egberts JH; Kalthoff H; Trauzold A
BMC Cancer; 2018 Jul; 18(1):777. PubMed ID: 30064384
[TBL] [Abstract][Full Text] [Related]
2. Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells.
Haselmann V; Kurz A; Bertsch U; Hübner S; Olempska-Müller M; Fritsch J; Häsler R; Pickl A; Fritsche H; Annewanter F; Engler C; Fleig B; Bernt A; Röder C; Schmidt H; Gelhaus C; Hauser C; Egberts JH; Heneweer C; Rohde AM; Böger C; Knippschild U; Röcken C; Adam D; Walczak H; Schütze S; Janssen O; Wulczyn FG; Wajant H; Kalthoff H; Trauzold A
Gastroenterology; 2014 Jan; 146(1):278-90. PubMed ID: 24120475
[TBL] [Abstract][Full Text] [Related]
3. Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery.
Gallmeier E; Bader DC; Kriegl L; Berezowska S; Seeliger H; Göke B; Kirchner T; Bruns C; De Toni EN
PLoS One; 2013; 8(2):e56760. PubMed ID: 23460812
[TBL] [Abstract][Full Text] [Related]
4. The expression of death receptor systems TRAIL-R1/-R2/-R4, CD95 and TNF-R1 and their cognate ligands in pancreatic ductal adenocarcinoma.
Gaertner F; Krüger S; Röder C; Trauzold A; Röcken C; Kalthoff H
Histol Histopathol; 2019 May; 34(5):491-501. PubMed ID: 30375637
[TBL] [Abstract][Full Text] [Related]
5. Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1.
Radke DI; Ungefroren H; Helm O; Voigt S; Alp G; Braun H; Hübner S; Dilchert J; Sebens S; Adam D; Kalthoff H; Trauzold A
Cell Signal; 2016 Nov; 28(11):1652-62. PubMed ID: 27492861
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of high mobility group A2 (HMGA2) in pancreatic ductal adenocarcinoma: malignant functions of cytoplasmic HMGA2 expression.
Gundlach JP; Hauser C; Schlegel FM; Willms A; Halske C; Röder C; Krüger S; Röcken C; Becker T; Kalthoff H; Trauzold A
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3313-3324. PubMed ID: 34302528
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer.
Ganten TM; Sykora J; Koschny R; Batke E; Aulmann S; Mansmann U; Stremmel W; Sinn HP; Walczak H
J Mol Med (Berl); 2009 Oct; 87(10):995-1007. PubMed ID: 19680616
[TBL] [Abstract][Full Text] [Related]
8. TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme.
Kuijlen JM; Mooij JJ; Platteel I; Hoving EW; van der Graaf WT; Span MM; Hollema H; den Dunnen WF
J Neurooncol; 2006 Jun; 78(2):161-71. PubMed ID: 16544055
[TBL] [Abstract][Full Text] [Related]
9. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
10. High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients.
Sanlioglu AD; Dirice E; Elpek O; Korcum AF; Ozdogan M; Suleymanlar I; Balci MK; Griffith TS; Sanlioglu S
Pancreas; 2009 Mar; 38(2):154-60. PubMed ID: 18981952
[TBL] [Abstract][Full Text] [Related]
11. TRAIL-induced expression of uPA and IL-8 strongly enhanced by overexpression of TRAF2 and Bcl-xL in pancreatic ductal adenocarcinoma cells.
Zhou DH; Yang LN; Roder C; Kalthoff H; Trauzold A
Hepatobiliary Pancreat Dis Int; 2013 Feb; 12(1):94-8. PubMed ID: 23392805
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of NEDD9, E-cadherin and γ-catenin and their prognostic significance in pancreatic ductal adenocarcinoma (PDAC).
Radulović P; Krušlin B
Bosn J Basic Med Sci; 2018 Aug; 18(3):246-251. PubMed ID: 29924959
[TBL] [Abstract][Full Text] [Related]
13. Small Nucleolar Noncoding RNA SNORA23, Up-Regulated in Human Pancreatic Ductal Adenocarcinoma, Regulates Expression of Spectrin Repeat-Containing Nuclear Envelope 2 to Promote Growth and Metastasis of Xenograft Tumors in Mice.
Cui L; Nakano K; Obchoei S; Setoguchi K; Matsumoto M; Yamamoto T; Obika S; Shimada K; Hiraoka N
Gastroenterology; 2017 Jul; 153(1):292-306.e2. PubMed ID: 28390868
[TBL] [Abstract][Full Text] [Related]
14. Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma.
Cai L; Michelakos T; Ferrone CR; Zhang L; Deshpande V; Shen Q; DeLeo A; Yamada T; Zhang G; Ferrone S; Wang X
Oncotarget; 2017 Jun; 8(23):37646-37656. PubMed ID: 28430580
[TBL] [Abstract][Full Text] [Related]
15. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z
Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological correlations of nestin expression in surgically resectable pancreatic cancer including an analysis of perineural invasion.
Lenz J; Karasek P; Jarkovsky J; Muckova K; Dite P; Kala Z; Veselska R; Hermanova M
J Gastrointestin Liver Dis; 2011 Dec; 20(4):389-96. PubMed ID: 22187705
[TBL] [Abstract][Full Text] [Related]
17. IL-8-Positive Tumor-Infiltrating Inflammatory Cells Are a Novel Prognostic Marker in Pancreatic Ductal Adenocarcinoma Patients.
Fang Y; Saiyin H; Zhao X; Wu Y; Han X; Lou W
Pancreas; 2016; 45(5):671-8. PubMed ID: 26495785
[TBL] [Abstract][Full Text] [Related]
18. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
19. Jagged1 and DLL4 expressions in benign and malignant pancreatic lesions and their clinicopathological significance.
Huang SF; Yang ZL; Li DQ; Liu ZY; Wang CW; Miao XY; Zou Q; Yuan Y
Hepatobiliary Pancreat Dis Int; 2016 Dec; 15(6):640-646. PubMed ID: 27919854
[TBL] [Abstract][Full Text] [Related]
20. TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill.
Mohr A; Yu R; Zwacka RM
BMC Cancer; 2015 Jul; 15():494. PubMed ID: 26138346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
